Ocumension Therapeutics Reports NMPA NDA Acceptance of OT-301 to Lower Intraocular Pressure

Shots: The NMPA has accepted NDA for OT-301(bimatoprost grenod; NCX 470) to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension The NDA was backed by the P-III (Mont Blanc & Denali) trial data, where Mont Blanc’s 1EP showed robust efficacy & safety, plus Denali met its 1EP of non-inferiority of OT-301 as…

ByRidhi RastogiSeptember 11, 2026

The US FDA Accepts Nicox’s NDA for NCX 470 in Glaucoma

Shots: The FDA has accepted NDA for NCX 470 (bimatoprost grenod) to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension (PDUFA: Apr 30, 2027) The NDA, submitted by US licensee Kowa, is supported by P-III (Mont Blanc & Denali) trial data showing IOP reductions of up to 10mmHg with a favorable safety…

ByRidhi RastogiAugust 28, 2026

Nicox and Kowa Enter a Licensing Agreement for NCX 470 to Treat Glaucoma

Shots: Nicox has granted Kowa exclusive global rights to develop & commercialize NCX 470 for glaucoma or ocular hypertension, excl. territories already licensed to Ocumension (China, Korea & Southeast Asia) & to Kowa (Japan) As per the deal, Nicox will receive $8.7M (€7.5M) upfront & near-term milestones tied to positive topline P-III (Denali) trial data…

ByRidhi RastogiJuly 17, 2025

Ocumension Therapeutics Reports NMPA NDA Acceptance of OT-301 to Lower Intraocular Pressure

The US FDA Accepts Nicox’s NDA for NCX 470 in Glaucoma

Nicox and Kowa Enter a Licensing Agreement for NCX 470 to Treat Glaucoma

Contact US

FOLLOW US